Navigation Links
Onyx Pharmaceuticals Announces First Quarter 2011 Financial Results Teleconference and Webcast
Date:4/21/2011

SAN FRANCISCO, April 21, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to discuss first quarter 2011 financial results, as well as provide a general business overview on Wednesday, May 4, 2011, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time; 2:00 p.m. Central European Time).  Financial results for the first quarter ended March 31, 2011 will be released earlier that day.

Interested parties may access a live webcast of the presentation on the company's website at: http://www.onyx-pharm.com/investors/event-calendarWithin the U.S.:

888-771-4371International:

847-585-4405Passcode:

29609004#A replay of the presentation will be available on the Onyx website or by dialing:Dial in:

630-652-3042 Passcode:

29609004# (approximately one hour after the teleconference concludes)  The replay will be available through May 18, 2011. About Onyx Pharmaceuticals, Inc.Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma in various settings and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results
2. Fleming Pharmaceuticals Now Ready to Step Up Production of Nuclear Radiation Safeguard, ThyroShield®
3. Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
4. Hanmi Pharmaceuticals to Acquire the Rights for a Promising Phase II Anti-cancer Src Kinase/Pretubulin Dual Inhibitor from Kinex Pharmaceuticals, in Selected Asian Territories
5. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
6. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
8. Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering
9. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
10. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
11. Bexion Pharmaceuticals Receives Outstanding Biotech Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... CAMBRIDGE, England and DEERFIELD, Ill. ... U.S.A. , Inc., a wholly-owned subsidiary ... Limited, a joint venture between Cambridge Cognition Holdings PLC ... the use of a specially designed app on an ... in patients with Major Depressive Disorder (MDD). ...
(Date:2/23/2017)...  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: ... fourth quarter and full year 2016 financial results on Thursday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at 4:30 ... be obtained as follows: Thursday, March 2 ...
(Date:2/22/2017)... Feb. 22, 2017  Andre, DiMino, CEO of ADM ... manufacturer of innovative technologies and products, commented on ADMT,s ... February 21, 2017 in the Company,s quarterly report on ... ADMT CEO Andre, DiMino stated "During the quarter ended ... by devoting a larger portion of our engineering efforts ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... When it came time to ... in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s grand opening presented ... $51 million to purchase and renovate the 185,000 square-foot office complex, which was ...
(Date:2/22/2017)... Raton, FL (PRWEB) , ... February 22, 2017 , ... ... primarily from deer antler velvet, announced its products are coming soon to Amazon.com, the ... Clint and Shelley Thomson as a means to develop an effective natural treatment for ...
(Date:2/22/2017)... ... February 22, 2017 , ... The Waismann Method® is providing a ... have recently fallen victim to America’s opioid epidemic. Now, opiate dependent individuals can be ... are free from the shame, stigma, and harmful labeling believed to prevent ...
(Date:2/22/2017)... ... February 22, 2017 , ... The National Academy of Certified ... the April 2017 testing period. NACCM, a nonprofit organization, has provided the premier ... exam is periodically re-calibrated to ensure that newly certified professionals are prepared to ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving patients with diabetes ... emergency room, fewer hospital admissions, and better blood pressure and glycemic control, a ... The study can be found here . , The study comes as ...
Breaking Medicine News(10 mins):